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Abstract
Background: We previously identified a panel of genes associated with outcome of ovarian cancer. The purpose of the
current study was to assess whether variants in these genes correlated with ovarian cancer risk.
Methods and Findings: Women with and without invasive ovarian cancer (749 cases, 1,041 controls) were genotyped at 136
single nucleotide polymorphisms (SNPs) within 13 candidate genes. Risk was estimated for each SNP and for overall
variation within each gene. At the gene-level, variation within MSL1 (male-specific lethal-1 homolog) was associated with
risk of serous cancer (p=0.03); haplotypes within PRPF31 (PRP31 pre-mRNA processing factor 31 homolog) were associated
with risk of invasive disease (p=0.03). MSL1 rs7211770 was associated with decreased risk of serous disease (OR 0.81, 95% CI
0.66–0.98; p=0.03). SNPs in MFSD7, BTN3A3, ZNF200, PTPRS, and CCND1A were inversely associated with risk (p,0.05), and
there was increased risk at HEXIM1 rs1053578 (p=0.04, OR 1.40, 95% CI 1.02–1.91).
Conclusions: Tumor studies can reveal novel genes worthy of follow-up for cancer susceptibility. Here, we found that
inherited markers in the gene encoding MSL1, part of a complex that modifies the histone H4, may decrease risk of invasive
serous ovarian cancer.
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Introduction
Worldwide, there are approximately 125,000 deaths each year
due to ovarian cancer [1]; increased understanding of factors
related to its outcome and etiology should reduce the burden of
this disease. We previously reported results of tumor mRNA
expression studies which suggested that altered expression of a
particular set of genes predicted response to chemotherapy among
women with advanced-stage high-grade epithelial ovarian cancer
[2]. These genes included SF3A3, MFSD7 (formerly known as
FLJ22269), ID4, BTN3A3, OSGIN2 (formerly known as C8orf1),
FARP1, PRKCH, C15orf15, ZNF200, MSL1 (formerly known as
LOC339287), HEXIM1 (formerly known as HIS1), PTPRS,
CC2D1A (formerly known as FLJ20241), and PRPF31. Expression
levels differed among tumors from women with differing
outcomes; namely, in combination, expression of these genes
predicted early relapse (,21 months) after optimal surgery and
platinum-paclitaxel chemotherapy with an accuracy of 86% and
positive predictive value of 95% [3,2].
The etiology of ovarian cancer is known to be complex and,
at least in part, includes inherited susceptibility factors.
Mutations in BRCA1, BRCA2, MLH1,a n dMSH2 account for
approximately 50% of familial ovarian cancer [4,5], and
remaining cases with a family history are likely due to
combinations of multiple alleles conferring low to moderate
penetrant susceptibility [6,7] such as variants in BNC2 [8] and,
possibly, TP53 [9], CDKN2A [10], CDKN1B [10], and AURKA
[11]. As a complement to genome-wide searches, a useful
approach for the identification of additional low-risk alleles is
the study of highly-informative inherited variants in candidate
genes identified from tumor expression studies. To assess
whether variation in genes with differing expression levels by
outcome influenced risk of ovarian cancer, we conducted a case-
control analysis of inherited variants in genes in the predictive
model mentioned above [2] as well as in HTRA1 (encoding the
serine protease HtrA1) which we have shown is down-regulated
in a majority of ovarian tumors [12,13] and has a key role in
apoptosis [13]. As the first examination of germline variation in
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elucidate their role in epithelial ovarian carcinogenic processes.
Results
Demographic, reproductive, lifestyle, and tumor characteristics
of 749 epithelial invasive ovarian cancer patients and 1,041
controls are described in Table 2. Generally, the expected
distributions of risk factors were observed; a greater proportion
of patients than controls had never used oral contraceptives
(p,0.001), had used hormone therapy (p,0.001), were nullipa-
rous (p=0.01), and had a first or second degree family history of
ovarian cancer (p,0.001). Such factors associated with risk of
ovarian cancer were included as covariates in all genetic analyses.
Gene-level and selected SNP-level association-testing results are
shown in Table 3 and Table 4, respectively. Associations for the
full set of SNPs examined are displayed in Table S1. Of genes
examined in relation to risk of invasive ovarian cancer and risk of
invasive serous ovarian cancer, only global variation in the MSL1
and PRPF31 genes was associated at p,0.05. MSL1 gene-level
principal components (summarized combinations of genotypes
based on two SNPs) were associated with risk of invasive serous
disease (p=0.03). At one of the two SNPs in this gene, rs7211440
(r
2=0.53 with rs17678694; Figure S1), carriage of the minor allele
was associated with reduced risk of both invasive and invasive
serous disease (OR 0.85, 95% CI 0.72–1.00, p=0.05; OR 0.81,
95% CI 0.66–0.98, p=0.03, respectively, Table 4), suggesting this
SNP as the primary driver of MSL1’s gene-level serous association.
PRPF31 haplotypes (consecutive series of alleles based on eight
SNPs) were associated with risk of invasive disease (p=0.03). As
haplotype analysis can reveal hidden associations, we more closely
examined the twenty-six common haplotypes within PRPF31
(Table S2). Compared to the most common haplotype 11111111
(major alleles at all PRPF31 SNPs), the haplotype 10101111
(minor alleles at intronic tagging single nucleotide polymorphisms
(tagSNPs) rs12985735 and rs254272) conferred reduced risk of
invasive ovarian cancer (OR 0.22, 95%CI 0.06–0.82, p=0.02).
These two SNPs were only modestly correlated (r
2=0.23; Figure
S1), and neither was independently associated with risk
(rs12985735 per allele OR 1.13, 95% CI 0.98–1.30, p=0.10;
rs254272 per allele OR 1.05, 95% CI 0.89–1.25, p=0.56),
suggesting that an ungenotyped variant in close proximity to the
PRPF31 haplotype may contribute to the association. As two other
PRPF31 haplotypes were associated with ovarian cancer risk at
p,0.10 (00111101 OR 2.81, 95% CI 0.85–9.22, p=0.09;
10101101 OR 2.86, 95% CI 0.94–8.71, p=0.06), other variants
in the gene may also contribute to the observed global haplotype
association.
Outside of the two gene-level associated genes (MSL1 and
PRPF31), a small number of SNPs in six other genes were
associated at the single-SNP level (p,0.05, Table 4) including
three SNPs associated with reduced risk of both invasive and
invasive serous disease (in CC2DIA, MFSD7, and ZNF200). The
strongest SNP-level association was observed at the non-
synonymous rs2305777 (T801M) in the NF-kB activating gene
CC2D1A (invasive OR 0.84, 95% 0.72–0.99, p=0.03; serous
invasive OR 0.76, 95% CI 0.62–0.99 p=0.005). Based on
sequence conservation across species [14], this SNP is predicted
to be relatively undamaging to protein function. Because this
SNP was not correlated with other genotyped SNPs (r
2,0.12,
Figure S1) and did not tag other common HapMap SNPs at
r
2.0.9, sequencing may be required to clarify the meaning of this
SNP association. Similarly, MFSD7 rs6840253 was associated
with a reduction of ovarian cancer risk (invasive OR 0.81, 95%
CI 0.66–1.0, p=0.05; serous invasive OR 0.76, 95% CI 0.58–
0.98, p=0.03), as was ZNF200 rs186493 (invasive OR 0.83, 95%
0.71–0.82, p=0.02; invasive serous OR 0.82, 95% CI 0.68–0.98,
p=0.03). Both are promoter region SNPs (within 5 kb 59
upstream) and independent of other HapMap SNPs at r
2.0.9.
Table 1. Candidate genes of interest.
Chr. Gene Name Description GeneID Refseq Start (bp) Size (kb) Str.
N SNPs (N
Attempted)
1 SF3A3 Splicing factor 3a, subunit 3, 60 kDa 10946 NM_006802.2 38,195,239 33.1 - 8 (8)
4 MFSD7 Major facilitator superfamily domain containing 7 84179 NM_032219.2 665,618 7.4 - 3 (3)
6 ID4 Inhibitor of DNA binding 4, dominant negative
helix-loop-helix protein
3400 NM_001546.2 19,945,596 3.3 + 9 (9)
BTN3A3 Butyrophilin, subfamily 3, member A3 10384 NM_006994.3 26,548,742 12.9 + 13 (13)
8 OSGIN2 Oxidative stress induced growth inhibitor family
member 2
734 NM_004337.1 90,983,269 26.0 + 6 (7)
10 HTRA1 HtrA serine peptidase 1 5654 NM_002775.3 124,211,047 53.4 + 27 (27)
15 C15orf15 Chromosome 15 open reading frame 15 51187 NM_016304.2 53,260,804 15.7 - 15 (15)
16 ZNF200 Zinc finger protein 200 7752 NM_198087.1 3,212,343 13.1 - 5 (5)
17 MSL1 Male-specific lethal-1 homolog (Drosophila) 339287 NM_001012241.1 35,532,278 14.4 + 2 (2)
HEXIM1 Hexamethylene bis-acetamide inducible 1 10614 NM_006460.2 40,580,467 4.8 + 3 (3)
19 PTPRS Protein tyrosine phosphatase, receptor type, S 5802 NM_002850.3 5,109,506 182.3 - 28 (28)
CC2D1A Coiled-coil and C2 domain containing 1A 54862 NM_017721.3 13,878,052 24.6 + 7 (8)
PRPF31 PRP31 pre-mRNA processing factor 31 homolog
(S. cerevisiae)
26121 NM_015629.2 59,310,649 16.3 + 8 (8)
Total 134 (136)
All genes are protein-coding and from UCSC (April 8, 2007) although MSL1 is from NCBI (September 6, 2007); names for several genes changed from previous citations:
MFSD7 was FLJ22269, OSGIN2 was C8orf1, MSL1 was LOC339287, HEXIM1 was HIS1,a n dCC2DIA was FLJ20241; N SNPs refers to number of tagSNPs or putative-functional
SNPs analyzed; FARP1 and PRKCH were excluded due to large gene size and low LD requiring over 100 tagSNPs each.
doi:10.1371/journal.pone.0008884.t001
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2.0.6 with other genotyped SNPs,
additional genotyping of modestly correlated SNPs could help
elucidate these associations.
Three SNPs were associated only with reduced risk of invasive
serous disease (in PTPRS and BTN3A3), and one SNP associated
with increased risk of invasive serous disease (in HEXIM1). Thus,
while results were generally similar in both case groups, the often
greater statistical significance of results among women with serous
disease, despite reduced power due to a 40% smaller sample size,
suggests that subtype analysis revealed heterogeneity by histology.
SNPs that were suggestive only in serous disease included two
highly-correlated PTPRS intron 9 SNPs (r
2=0.99; rs886936 OR
0.85, 95% CI 0.72–1.00, p=0.05; rs11878779 OR 0.79, 95% CI
0.66–0.95, p=0.01). Interestingly, these and three other highly-
correlated intron 9 SNPs (Figure S1) were independent of each
other in HapMap at r
2,0.9, serving as an example of non-
transferability of linkage disequilibrium (LD) across populations.
The only SNP with minor alleles associated with increased risk was
the potential HEXIM1 promoter region SNP rs1053578 (serous
OR 1.40, 95% CI 1.02–1.91, p=0.04) which was independent of
Table 2. Characteristics of study participants.
Patients (N=749) Controls (N=1,041) P-value
Age, years Mean (S.D.) 58.4 (11.8) 57 (12.8) 0.02
Self-reported race White 673 (91%) 944 (91%) 0.72
African American 54 (7%) 79 (8%)
Asian 6 (1%) 5 (,1%)
Other 9 (1%) 9 (,1%)
Missing 7 4
Body mass index, kg/m
2 ,23 173 (24%) 251 (25%) 0.17
23–26 169 (23%) 247 (25%)
26–29 166 (23%) 247 (25%)
.29 216 (30%) 248 (25%)
Missing 25 48
Oral contraceptive use Never 306 (42%) 346 (35%) ,0.001
1–48 Months 208 (29%) 253 (25%)
48+ Months 209 (29%) 400 (40%)
Missing 26 42
Hormone therapy Never 344 (49%) 588 (61%) ,0.001
1–60 Months 195 (28%) 185 (19%)
60+ Months 169 (24%) 190 (20%)
Missing 41 78
N children/age at first birth Nulliparous 140 (19%) 141 (14%) 0.01
122/,=20 yrs 76 (1%) 97 (10%)
122/.20 yrs 231 (31%) 365 (36%)
3+/,=20 yrs 134 (18%) 155 (15%)
3+/.20 yrs 158 (2%) 254 (25%)
Missing 10 29
1
st or 2
nd degree family Yes 85 (12%) 64 (6%) ,0.001
history of ovarian cancer No 655 (89%) 952 (94%)
Missing 9 25
Histologic sub-type Serous 452 (61%) - -
Endometrioid 126 (17%) -
Clear cell 55 (7%)
Mucinous 36 (5%) -
Other 77 (10%) -
Missing 3 -
Stage I 150 (20%) -
II 56 (8%) - -
III 452 (62%) -
IV 76 (10%) -
Missing 15
Data are counts (percentage) unless otherwise indicated. P-values are from t-test for continuous variables and Chi square test for categorical variables.
doi:10.1371/journal.pone.0008884.t002
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2,0.04 and of other HapMap SNPs at
r
2,0.9. BTN3A3’s putative promoter region SNP rs12206812 was
associated with reduced risk of serous invasive disease (OR 0.63,
95% CI 0.44–0.90, p=0.01); however, we suspect genotype or
genetic map error because of failure in WGA DNA and
independence with all other genotyped BTN3A3 SNPs (r
2=0;
Figure S1). No gene-level or SNP-level associations at p,0.05
were observed for SF3A3, ID4, OSGIN2, HTRA1,o rC15orf15.
Discussion
Knowledge about the genetics of ovarian cancer is in a rapid
state of expansion. As the most lethal gynecologic cancer,
discovery of inherited factors related to etiology and outcome
may assist in the development of important targeted prediction
and therapeutic strategies. Recent work has clarified the roles of
long-standing candidate SNPs in the progesterone receptor,
retinoblastoma, p53, and cell cycle genes [10,15,11,9] and enabled
genome-wide association studies [8]. Analysis of highly-informa-
tive variants in selective sets of novel genes complements these
candidate SNP and genome-wide association studies, providing
improved coverage in high-priority regions based on known tumor
biology [16]. Here, we selected novel candidate genes based on
prior evidence of their association with time to relapse of ovarian
cancer, and we chose comprehensive sets of variants [2,13]. Our
primary result is that variation in MSL1 was related to risk of
serous invasive ovarian cancer; notably, minor alleles at rs7211440
correlated with decreased risk (OR 0.81, 95% CI 0.66–0.98,
p=0.03). Previously, increased expression of MSL1 was correlated
with earlier time to relapse [2]; additional validation of the
prognostic model and replication of the etiologic association are
warranted.
MSL1 encodes one of five proteins that form the highly-
conserved MSL complex with enzymatic capabilities as a histone
acetyltransferase (HAT) [17]. HATs modify a variety of histone
domains through acetylation, which, along with other coactivators,
regulates histone and chromatin activation and influences gene
expression [18]. The MSL complex specifically acetylates lysine
residue 16 on histone H4 (H4-Lys16), which plays a crucial role in
regulating chromatin folding and silencing of gene expression
[19,20,17]. Knock-out models indicate that absence of the MSL
complex leads to malfunctions during the S phase of the cell cycle,
leading to errors in DNA replication [17]. Additionally, loss of
monoacetylation of H4-Lys16 and aberrant functioning on H4 are
hallmarks of cancer cells. Our data suggest that inherited variation
in MSL1 may impact risk of invasive serous ovarian cancer and are
consistent with findings that irregular H4 modifications may cause
errors in chromatin folding and gene expression and are
widespread in cancer phenotypes [21]. With suggestive SNPs in
genes for p53 and CDKN2A [10,9], which also regulate histone
modification, evidence for a role of inherited risk factors related to
histones is accumulating.
Strengths of this work include the use of two case-control study
populations (from Mayo Clinic and Duke University), advanced
SNP selection techniques (e.g., high level of required correlation
among alleles, inclusion of putative-functional SNPs, and selection
of multiple tagSNPs in large LD bins), and excellent genotyping
quality. Our assessment of risk for serous invasive disease
suggested a degree of genetic heterogeneity by histologic subtype;
however, we suggest caution in interpretation of results (particu-
larly single-SNP results in the absence of gene-level significance)
due to the relatively large number of tests performed. We also note
that no results are statistically significant after adjustment for
multiple testing using a conservative Bonferroni correction. Thus,
replication of our results is warranted to confirm these associa-
tions. Avenues for future research extending from this expression-
based candidate gene work include analysis of other histone
regulatory genes and detailed assessment of functional mecha-
nisms. More imminently, examination of promising SNPs within
MSL1 among a larger set of serous invasive patients and controls
and additional fine-scale mapping [16] will assist in clarification of
the importance of these genes to ovarian cancer susceptibility. This
should, in turn, inform translation of such findings to the clinical
management of women at increased risk for ovarian cancer.
Table 3. Gene-level results.
Invasive Disease (N=749) Invasive Serous Disease (N=452)
Chr. Gene N SNPs N PC N Haplotypes
PC
p-value
Haplotype
p-value
PC
p-value
Haplotype
p-value
1 SF3A3 8 3 55 0.74 0.80 0.53 0.16
4 MFSD7 3 3 7 0.19 0.51 0.19 0.73
6 ID4 9 4 86 0.30 0.52 0.24 0.69
BTN3A3 13 5 78 0.63 0.81 0.32 0.54
8 OSGIN2 6 3 19 0.90 0.30 0.92 0.49
10 HTRA1 27 9 27 0.84 0.78 0.90 0.18
15 C15orf15 15 4 65 0.24 0.47 0.37 0.46
16 ZNF200 5 3 16 0.10 0.42 0.13 0.36
17 MSL1 2 2 3 0.16 0.25 0.03 0.23
HEXIM1 3 3 5 0.30 0.45 0.24 0.14
19 PTPRS 28 13 26 0.52 0.73 0.46 0.95
CC2D1A 7 4 30 0.21 0.77 0.19 0.80
PRPF31 8 4 71 0.19 0.03 0.11 0.32
Analyses adjust for possible population structure (via principal components), study site, age, body mass index, hormone therapy, oral contraceptive use, number of live
births, age at first live birth, and geographic region; N PC represents the number of principal components included in analysis of invasive cases; N haplotypes represents
the estimated number of haplotypes with ten or more occurrences in the controls and invasive cases.
doi:10.1371/journal.pone.0008884.t003
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Chr. Gene rsid
bp to
previous Invasive Disease (N=749) Serous Invasive Disease (N=452)
per-allele OR (95% CI) p-value per-allele OR (95% CI) p-value
4 MFSD7 rs7690350 na 0.87 (0.66–1.16) 0.34 0.95 (0.69–1.32) 0.76
rs6840253 5,720 0.81 (0.66–1.00) 0.05 0.76 (0.58–0.98) 0.03
rs4690290 2,939 1.03 (0.89–1.18) 0.70 1.03 (0.87–1.21) 0.74
6 BTN3A3 rs4711110 na 0.91 (0.74–1.12) 0.39 0.80 (0.62–1.02) 0.08
rs12206812 779 0.81 (0.60–1.08) 0.15 0.63 (0.44–0.90) 0.01
rs10456330 100 1.17 (0.92–1.48) 0.20 1.26 (0.96–1.66) 0.10
rs12208390 414 1.15 (0.91–1.46) 0.24 1.24 (0.94–1.63) 0.12
rs9379874 3,323 0.99 (0.86–1.14) 0.91 0.94 (0.79–1.11) 0.44
rs17539219 113 0.98 (0.82–1.18) 0.86 0.89 (0.72–1.11) 0.32
rs12214444 110 0.91 (0.74–1.12) 0.36 0.79 (0.62–1.02) 0.07
rs13220495 988 1.00 (0.79–1.27) 0.99 0.88 (0.66–1.18) 0.39
rs9379875 3,092 0.93 (0.75–1.15) 0.50 0.86 (0.66–1.12) 0.27
rs3846845 183 1.01 (0.88–1.16) 0.90 0.95 (0.81–1.12) 0.56
rs1796524 4,304 1.16 (0.92–1.46) 0.21 1.11 (0.84–1.47) 0.45
rs6456723 6,286 0.92 (0.77–1.08) 0.31 0.89 (0.73–1.09) 0.26
rs2273193 3,020 0.96 (0.82–1.12) 0.58 0.98 (0.82–1.18) 0.86
16 ZNF200 rs12917706 na 0.92 (0.80–1.07) 0.28 0.93 (0.79–1.10) 0.39
rs401298 3,096 1.03 (0.90–1.20) 0.64 1.05 (0.88–1.24) 0.59
rs9927763 1,301 1.06 (0.81–1.39) 0.66 1.16 (0.85–1.59) 0.35
rs2075852 330 0.97 (0.85–1.12) 0.71 0.95 (0.80–1.12) 0.53
rs186493 6,726 0.83 (0.71–0.97) 0.02 0.82 (0.68–0.98) 0.03
17 MSL1 rs17678694 na 1.01 (0.68–1.48) 0.97 0.72 (0.43–1.19) 0.20
rs7211770 1,933 0.85 (0.72–1.00) 0.05 0.81 (0.66–0.98) 0.03
HEXIM1 rs1053578 .5.0 Mb 1.28 (0.97–1.69) 0.08 1.40 (1.02–1.91) 0.04
rs8070447 8,014 1.05 (0.85–1.29) 0.67 1.02 (0.80–1.30) 0.89
rs7217422 1,166 1.03 (0.84–1.25) 0.79 0.98 (0.77–1.23) 0.83
19 PTPRS rs8105746 na 0.97 (0.80–1.19) 0.80 1.05 (0.82–1.33) 0.72
rs1143700 5,919 1.05 (0.87–1.26) 0.61 1.00 (0.81–1.25) 0.98
rs1978237 2,866 1.00 (0.85–1.17) 0.99 0.97 (0.80–1.17) 0.72
rs2302224 981 1.12 (0.88–1.44) 0.35 1.03 (0.76–1.38) 0.86
rs2230611 1,860 1.04 (0.83–1.30) 0.73 1.06 (0.81–1.39) 0.67
rs11085118 1,676 1.03 (0.83–1.27) 0.81 1.01 (0.78–1.31) 0.95
rs10413063 2,125 1.03 (0.90–1.19) 0.66 1.05 (0.89–1.24) 0.55
rs12975955 3,520 0.95 (0.82–1.09) 0.47 0.98 (0.82–1.16) 0.79
rs10412973 1,097 1.00 (0.84–1.20) 1.00 0.98 (0.79–1.21) 0.84
rs12610082 6,108 1.15 (0.96–1.38) 0.13 1.15 (0.93–1.42) 0.19
rs4807015 4,127 0.93 (0.81–1.07) 0.32 0.94 (0.80–1.11) 0.47
rs2379609 5,031 1.14 (0.97–1.35) 0.11 1.15 (0.95–1.41) 0.15
rs3746130 4,226 1.03 (0.82–1.29) 0.81 1.00 (0.76–1.31) 0.98
rs10415488 6,325 1.02 (0.89–1.18) 0.75 1.04 (0.88–1.22) 0.68
rs886936 6,715 0.91 (0.79–1.04) 0.18 0.85 (0.72–1.00) 0.05
rs11878779 1,286 0.87 (0.75–1.01) 0.06 0.79 (0.66–0.95) 0.01
rs17130 252 1.08 (0.93–1.25) 0.31 1.10 (0.93–1.31) 0.27
rs4807016 3,520 1.00 (0.86–1.15) 0.99 0.98 (0.82–1.16) 0.78
rs2238640 3,016 1.07 (0.93–1.25) 0.34 1.09 (0.91–1.30) 0.36
rs1034863 6,245 0.93 (0.76–1.14) 0.47 0.96 (0.76–1.22) 0.75
rs933394 1,280 0.85 (0.63–1.14) 0.27 0.80 (0.56–1.15) 0.23
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Study Participants
Subjects participated in two ongoing case-control studies of
epithelial ovarian cancer initiated in January 2000 at Mayo Clinic
(Rochester, MN) and in May 1999 at Duke University (Durham,
NC). Details of the study design have been described in more
detail elsewhere [22–24]. Briefly, a total of 749 women with
histologically-confirmed invasive epithelial ovarian cancer and
1,041 controls without ovarian cancer and without bilateral
oophorectomy were recruited from the two study sites (Table 2;
site-specific characteristics provided in Table S3). At Mayo Clinic,
ovarian cancer cases (patients) were over 20 years of age with
histologically confirmed incident epithelial ovarian cancer and
enrolled in the study within one year after diagnosis. All cases seen
in the gynecologic or medical oncology units which lived in the six-
state region that defines the primary service population of Mayo
Clinic (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, and
South Dakota) were invited to participate. Controls were recruited
from among women seen for general medical examinations and
frequency-matched to patients on age and region of residence (i.e.,
state, county). At Duke University, patients were women with
histologically confirmed primary epithelial ovarian cancer, be-
tween 20 and 74 years of age, and identified within a 48-county
region using the North Carolina Central Cancer Registry.
Controls were identified using list-assisted random digit dialing
and frequency matched to patients on race, age, and county of
residence. No exclusions based on ethnicity were made. Applicants
provided written informed consent, and protocols were approved
by the Mayo Clinic and Duke University Institutional Review
Board.
Data and Biospecimen Collection
Information on potential risk factors was collected through in-
person interviews at both sites using similar questionnaires. DNA
was extracted from 10 to 15 mL fresh venous blood using the
Gentra AutoPure LS Purgene salting out methodology (Gentra,
Minneapolis, MN). DNA from Duke University participants were
transferred to Mayo Clinic for whole-genome amplification
(WGA) with the REPLI-G protocol (Qiagen Inc, Valencia CA)
which we have shown yielded highly-reproducible results [25].
DNA concentrations were adjusted to 50 ng/ml prior to
genotyping and verified using the PicoGreen dsDNA Quantitation
kit (Molecular Probes, Inc., Eugene OR). Samples were bar-coded
to ensure accurate and reliable processing.
SNP Selection
We identified tagSNPs within five kb of each candidate gene
using the algorithm of ldSelect [26] to bin pair-wise correlated
SNPs at r
2$0.90 with minor allele frequency (MAF) $0.05 in the
Chr. Gene rsid
bp to
previous Invasive Disease (N=749) Serous Invasive Disease (N=452)
per-allele OR (95% CI) p-value per-allele OR (95% CI) p-value
rs8110570 427 1.00 (0.82–1.23) 0.98 1.06 (0.83–1.34) 0.64
rs1141371 4,113 0.97 (0.82–1.14) 0.70 0.95 (0.78–1.15) 0.61
rs1034917 813 0.86 (0.70–1.06) 0.16 0.94 (0.74–1.19) 0.61
rs7254570 4,494 1.23 (0.93–1.62) 0.14 1.24 (0.90–1.71) 0.18
rs740058 9,304 0.90 (0.76–1.07) 0.23 0.94 (0.77–1.15) 0.55
rs4807711 2,173 0.92 (0.75–1.12) 0.42 1.00 (0.79–1.26) 0.98
rs758512 529 0.81 (0.60–1.09) 0.16 0.88 (0.63–1.23) 0.46
CC2D1A rs8111004 .8.6 Mb 1.07 (0.90–1.26) 0.45 1.08 (0.89–1.32) 0.43
rs3745457 4,609 1.09 (0.92–1.28) 0.31 1.10 (0.90–1.34) 0.34
rs6511901 10,878 1.09 (0.92–1.30) 0.32 1.13 (0.92–1.38) 0.24
rs2305777 11,139 0.84 (0.72–0.99) 0.03 0.76 (0.62–0.92) 0.005
rs1059721 2,810 1.14 (0.95–1.38) 0.17 1.10 (0.88–1.37) 0.40
rs2305778 2,686 0.89 (0.67–1.20) 0.45 0.97 (0.70–1.36) 0.87
rs2305779 746 0.97 (0.78–1.21) 0.78 0.93 (0.71–1.21) 0.59
PRPF31 rs4806711 .45 Mb 1.00 (0.84–1.20) 0.97 0.99 (0.80–1.22) 0.89
rs12985735 4,358 1.13 (0.98–1.30) 0.10 1.12 (0.94–1.33) 0.19
rs11670086 4,076 1.04 (0.84–1.29) 0.72 1.14 (0.89–1.47) 0.30
rs254272 2,072 1.05 (0.89–1.25) 0.56 1.08 (0.88–1.32) 0.47
rs10424816 511 1.03 (0.89–1.19) 0.71 1.05 (0.89–1.25) 0.55
rs254271 549 1.06 (0.92–1.23) 0.41 1.05 (0.89–1.25) 0.56
rs8102427 391 1.04 (0.90–1.20) 0.62 1.03 (0.87–1.23) 0.70
rs4806716 8,720 1.07 (0.90–1.26) 0.45 1.16 (0.95–1.41) 0.14
Results are shown for all SNPs in genes with a gene- or SNP-level p-value,0.05; bp to previous represents distance in base pairs between SNPs; odds ratios, 95%
confidence intervals and p-values from logistic regression analysis, adjusted for possible population structure (via principal components), study site, age, body mass
index, hormone therapy, oral contraceptive use, number of live births, age at first live birth, and geographic region; per-allele odds ratios and tests for trend p-values
based on an ordinal (log-additive) genotypic response; bold indicates p-value,0.05.
doi:10.1371/journal.pone.0008884.t004
Table 4. Cont.
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northern and western Europe) [27]. HapMap data were used
because, in November 2007, they were more informative for
these genes than data from Perlegen Sciences [28], Seattle SNPs
(http://pga.mbt.washington.edu), and NIEHS SNPs (http://
www.egp.gs.washingon.edu). One tagSNP per bin was selected
if less than ten SNPs were in a LD bin, and two tagSNPs per bin
were selected in LD bins with ten or more SNPs. Among
tagSNPs, SNPs were chosen to maximize Illumina SNP score (a
measure of predicted genotyping success) and then MAF. FARP1
(307 kb) and PRKCH (229 kb) required over 100 tagSNPs each
and were excluded from the study for cost-efficiency. For the
remaining genes (Table 1), 117 tagSNPs and 19 putative-
functional SNPs (within 10 kb upstream, 59 UTR, 39 UTR, or
non-synonymous from Ensembl version 34 with European-
American MAF$0.05 and Illumina SNP score$0.6) were
selected. Thus, a total of 136 SNPs in these 13 candidate genes
were genotyped.
Genotyping
As part of a larger study, genotyping of 2,176 DNA samples
(897 genomic, 1,279 WGA, and 129 duplicates) from 2,047
unique study participants was performed at Mayo Clinic along
with 65 laboratory controls. We used the Illumina GoldenGate
BeadArray assay and BeadStudio software for automated
clustering and calling according to a standard protocol [29]. Of
2,047 participants genotyped, 44 samples (2.1%) failed (call
rate ,90%), and 213 participants (10.4%) were found to be
ineligible or have borderline disease and were excluded; thus
1,790 participants (including 749 patients with invasive disease
and 1,041 controls) were analyzed here. A total of 1,152 SNPs for
a variety of projects were attempted; 25 failed SNPs included 15
(1.3%) with call rate ,90%, nine (0.8%) with poor clustering, and
one (,0.1%) with unresolved replicate or Mendelian errors in
genomic DNA. We assessed departures from Hardy Weinberg
equilibrium (HWE) in self-reported white, non-Hispanic controls
with a Pearson goodness-of-fit test or, in the case of SNPs with a
MAF ,5%, a Fisher exact test, and we excluded SNPs with
MAF ,0.01 (N=64, 5.6%) or HWE p-value,0.0001 (N=11,
1.0%), leaving 1,052 SNPs for analysis. For WGA DNA, an
additional 20 SNPs (1.7%) were excluded due to one or more of
the above criteria. Among the 13 candidate genes studied, 134 of
136 SNPs were successfully genotyped in genomic samples, and
all but six of these were also genotyped successfully in WGA
samples (Table S4).
Statistical Methods
Distributions of demographic and clinical variables were
compared between patients and controls using chi-square tests
or t-tests, and estimates of pair-wise LD between SNPs were
obtained using Haploview software, version 4.1 [30]. Genetic
association analyses (described below) were adjusted for study site,
age, body mass index, hormone therapy, oral contraceptive use,
number of live births, age at first live birth, and population
structure principal components which accounted for the possibility
of population stratification using an approach similar to that
described previously [31]. Population structure principal compo-
nents were created using 2,517 SNPs from this and prior
genotyping panels [23]; scatter plot matrices by self-reported race
indicated that the first four population structure principal
components reasonably approximated racial differences across
individuals and were thus included as covariates in all models
(Figure S2).
Associations with ovarian cancer risk were assessed using
logistic regression of SNPs, gene-level principal components, and
gene-level haplotypes. For SNPs, odds ratios (OR) and 95%
confidence intervals (CI) were estimated separately for heterozy-
gous and homozygous minor allele genotypes, using the
homozygous major allele genotype as the referent group. We
included eight SNPs with HWE,0.05 (Table S4) because of
acceptable genotype cluster plots, the large number of tests
(Bonferroni corrected p-value#3.7610
24), and no assumption of
HWE for single-SNP analysis. Formal genotypic tests of
association were carried out assuming an ordinal (log-additive)
effect using simple tests for trend. Within each gene, we used a
principal component analysis to create orthogonal linear
combinations of the SNP minor allele count variables (including
genotypes imputed using the MACH software package [32]) to
provide an alternate and equivalent representation of the
collection of SNPs as a whole. The resulting smallest subset of
gene-level principal components that accounted for at least 90%
of the SNP variability was included in regression models, and
gene-specific associations were evaluated using a multiple degree
of freedom likelihood ratio test. Gene-centric haplotype-based
association analyses were conducted using posterior probabilities
of all possible haplotypes for an individual (excluding SNPs with
HWE p-value,0.05), conditional on the observed genotypes.
The expectation-maximization algorithm was used to estimate
haplotypes [33] and create haplotype design variables ranging
from 0 to 2. Because of the imprecision involved in low-frequency
haplotypes, we excluded haplotypes with an estimated frequency
of less than ten. Assessments of risk among common haplotypes
tested the simultaneous effects of all haplotypes combined in
logistic regression; individual haplotype associations used the
most common haplotype as reference. All statistical tests were
two-sided, and unless otherwise indicated, were carried out using
SAS software (SAS Institute, Inc., Cary, NC).
Supporting Information
Figure S1 Linkage disequilibrium plots. Genes with gene-level
or SNP-level p,0.05 are shown; Haploview 4.1 (Barrett et al.,
2005) based on self-reported white-non-Hispanic controls;
r2=0=white and r2=1=black; numbers represent r2 * 100.
Found at: doi:10.1371/journal.pone.0008884.s001 (1.04 MB
DOC)
Figure S2 Matrix of scatterplots for four population structure
principal components by self-reported race. Population structure
principal components analysis based on 1,981 participants and
2,517 SNPs including imputed genotypes; for each scatterplot,
vertical axis corresponds to the component listed in diagonal
element to the left of the plot, and horizontal axis corresponds to
the component listed in diagonal underneath the plot; results
suggest that the first component differentiated white non-Hispanic
and black non-Hispanic from other samples, while the fourth
component helped to further differentiate Asian from other
samples; these four population structure principal components
were used as covariates in association testing.
Found at: doi:10.1371/journal.pone.0008884.s002 (0.30 MB
DOC)
Table S1 SNPs and risk of ovarian cancer, OR (95% CI)
Found at: doi:10.1371/journal.pone.0008884.s003 (0.43 MB
DOC)
Table S2 Haplotype results for PRPF31 (global p-value=0.03)
Found at: doi:10.1371/journal.pone.0008884.s004 (0.12 MB
DOC)
Relapse Genes & Ovarian Cancer
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8884Table S3 Characteristics of study participants by study site
Found at: doi:10.1371/journal.pone.0008884.s005 (0.14 MB
DOC)
Table S4 SNP and genotype information
Found at: doi:10.1371/journal.pone.0008884.s006 (0.56 MB
DOC)
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